Broadcom named strategic vendor for Walmart virtualization solutions
Investing.com - Axsome Therapeutics Inc (NASDAQ: AXSM) reported first quarter EPS of $-1.22, $0.08 better than the analyst estimate of $-1.30. Revenue for the quarter came in at $121.46M versus the consensus estimate of $121.58M.
Axsome Therapeutics Inc’s stock price closed at $112.21. It is down -1.57% in the last 3 months and up 47.76% in the last 12 months.
Axsome Therapeutics Inc saw 0 positive EPS revisions and 7 negative EPS revisions in the last 90 days. See Axsome Therapeutics Inc’s stock price’s past reactions to earnings here.
According to InvestingPro, Axsome Therapeutics Inc’s Financial Health score is "fair performance".
Check out Axsome Therapeutics Inc’s recent earnings performance, and Axsome Therapeutics Inc’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar